Free 2-Day Shipping on Orders Over $200
TB-500 is a synthetic fragment associated with thymosin beta-4 research, where laboratory work has focused on actin interactions, cell migration, and sequence-specific activity.
TB-500 is commonly described as a short synthetic peptide derived from the actin-binding protein thymosin beta-4. The sequence most often discussed in this context contains the central LKKTETQ motif. Because thymosin beta-4 and the shorter commercial fragment are not interchangeable research materials, findings involving the full-length protein should not automatically be assigned to TB-500.
In vitro work has shown that thymosin beta-4 can regulate actin dynamics and that a synthetic peptide containing the LKKTETQ sequence can influence endothelial-cell migration and tube formation under defined culture conditions. Structural studies have also examined how beta-thymosins contact actin, helping define the molecular basis of this protein-peptide interaction.
The literature supports TB-500 as a useful subject for sequence, binding, and cell-migration research. It does not establish that a commercial TB-500 preparation will reproduce findings reported for full-length thymosin beta-4, and it does not establish safety, efficacy, dosing, administration, or an expected outcome in humans or animals.
Peer-reviewed sources for the research summarised above. Vivo summarises published, third-party science and does not conduct or sponsor this research.